Yver Antoine 的 Form 4/A 修正申報
修正Centessa Pharmaceuticals plc（CNTA），2022/11/23 申報
- 申報編號
- 0001847903-22-000096
- 申報時間
- 2022/11/23
- 交易日
- 2022/10/3
- 申報延遲
- 51 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2022/10/4
這份申報列了 1 筆非衍生性交易。沿用原件裡沒有重述的 1 筆交易。公開市場賣出合計 $4.72 萬。交易後 51 天申報。
這份修正申報重述了 0001847903-22-000065（2022/10/4 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Yver AntoineCIK 0001861878 | 高階主管（EVP & Chairman of Development） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2022/10/3 | Ordinary Shares | S賣出處分 | −9,500 | $3.91F4 | −$37,145 | 780,251 | 直接 |
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0001847903-22-000065（2022/10/4 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2022/9/30 | Ordinary Shares | S賣出處分 | −2,468 | $4.07F3 | −$10,044.76 | 787,283 | 直接 |
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.93 to $4.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
表 I 有 1 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2
The transaction on September 30, 2022 previously reported on the Form 4 filed on October 4, 2022 was canceled in its entirety before settlement by the broker without instruction from the Issuer or Reporting Person.
- F3
The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted shares. These sales were automatic and intended to qualify under Rule 10b5-1.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.8800 to $3.9250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The Form 4 filed on October 4, 2022 reported an aggregate of 12,524 shares sold on October 3, 2022, of which (i) the transaction for the sale of 3,024 shares was canceled in its entirety before settlement by the broker without instruction from the Issuer or Reporting Person and (ii) 9,500 shares were sold as previously reported on the Form 4. No additional sales are being reported herein.
- F6
This amendment shall also be deemed to correct the total beneficial ownership reported by the Reporting Person in the subsequently filed Form 4 on November 3, 2022.